Factive supplemental approval
Executive Summary
FDA approves GeneSoft's Factive (gemifloxacin) for use in community-acquired pneumonia in multi-drug resistant S. pneumoniae strains July 25 (1"The Pink Sheet" April 14, 2003, p. 15)...
You may also be interested in...
GeneSoft Factive Surveillance Program Will Track Appropriate Prescribing
GeneSoft will track Factive antibiotic prescribing patterns to determine whether labeling adequately promotes short-term use of the drug
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.